Medtronic Bets On Tuck-In Deals And CAS Momentum To Sustain Growth Into Fiscal 2027
The medtech giant closed out fiscal 2026 with double-digit cardiovascular gains and a string of acquisitions, while bracing for $250m in tariff headwinds.
Medtech Insight - June 4, 2026

Fractyl’s One-Time Procedure Shows Durable Weight Control A Year After GLP-1 Withdrawal
Open-label data show 78% weight-loss retention at one year post-GLP-1 discontinuation, as Fractyl advances toward a De Novo filing and reimbursement synchronized under the new RAPID pathway.
Medtech Insight - June 4, 2026

Hikma Overtakes US Xeljanz Exclusivity As Tablets Loom Larger
Hikma’s launch of a generic version of Xeljanz oral solution, though small in scale, highlights Slayback’s first-filer status, widening generic competition and the much bigger tablet opportunity now opening up.
Generics Bulletin - June 4, 2026

Endo Creditors Fight On In $4bn Par-TPG Dispute
A bankruptcy judge has let Endo’s trustee keep pursuing Par’s former owner TPG over allegations that Endo significantly overpaid for Par in 2015, while dismissing opioid contribution claims and claims against former Par executives.
Generics Bulletin - June 4, 2026

EU Urban Wastewater ‘Producer Pays’ Provisions Could Fall Before Implementation
At the 62nd AESGP Annual Meeting, Squire Patton Boggs' Manon Ombredane sets out the four simultaneous legal challenges to the UWWTD's extended producer responsibility provisions and the timelines that could see them struck down before member states are required to transpose them.
HBW Insight - June 4, 2026

‘Too Badly Designed To Work’ – Industry Lays Into EU Urban Wastewater Directive
At the 62nd AESGP Annual Meeting in Berlin, president Jonathan Workman and Pharma Deutschland's Lutz Boden line up against the EU Urban Wastewater Treatment Directive as PwC analysis suggests industry may be overcharged by a factor of 50.
HBW Insight - June 4, 2026

ASCO: DAC Throws Hat In SCLC Ring With Anti-CD56 ADC
Phase I data show Hangzhou DAC’s CD56-targeting antibody-drug conjugate DXC006 yielded an unconfirmed 75% objective response rate in second-line small cell lung cancer, while CD56-related toxicities were low.
Scrip - June 4, 2026

The CEO Who Wants to Make Tacrolimus History
Eledon CEO David-Alexandre Gros is advancing tegoprubart, a CD40L blocker showing dramatically fewer side effects than tacrolimus, toward Phase III kidney transplant trials and beyond.
In Vivo - June 4, 2026

Spain’s Ona Advances ADCs Into Clinic After Cash Boost
Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m.
Scrip - June 4, 2026

US CIR To Revisit Kojic Acid In Light Of EU Restriction; Welcomes Panel Member
The Cosmetic Ingredient Review Expert Panel plans to review the safety of kojic acid and welcomes Dr. Bruce Brod as the newest panel member in advance of its 176th meeting on June 15-16.
HBW Insight - June 4, 2026